X
-linked acrogigantism (XLAG) is a recently described clinical syndrome of early-onset gigantism with typical onset in the first few months of life and more often affecting females (1) (2) (3) . The disease is associated with microduplications at Xq26.3 involving the GPR101 gene, which encodes a G protein-coupled orphan receptor.
Most of the patients present with a GH and prolactin (PRL)-secreting pituitary adenoma or less commonly GH and PRL cell hyperplasia. The vast majority of the previously described patients required extensive anterior pituitary resection or radiotherapy, resulting in hypopituitarism to control exuberant hormone secretion and growth velocity, because medical management with somatostatin analogs has not been sufficient (3).
Case Report and Methods
A 4-year and 8-month-old Caucasian boy presented to the Montreal Children's Hospital with rapid growth over the preceding 2 years. Born at term with a weight of 4.7 kg (Ͼ95th percentile), he had grown steadily along the 90th percentile for length up to 24 months of age and was above the median for weight and head circumference. He had undergone a tonsillectomy and adenoidectomy at the age of 3 years and 10 months. He complained of intermittent headaches over the preceding 8 months, was otherwise asymptomatic, and took no medications. His family history was unremarkable for any endocrinopathies; his midparental height was 174.5 cm. On examination, he appeared older than his stated age, was prepubertal, and had coarse facial features, which had developed over the previous 3 years. His height was 129.7 cm (Z ϭ ϩ4.89), and his weight was 35.5 kg (Z ϭ ϩ5.57) (WHO Growth Charts for Canada; Ref. 4) ( Figure 1A) . Postoperatively, his hormone levels remained elevated; the hyperplastic tissue re-expanded rapidly in the fossa (Figure 1, E and F) , and his growth continued at an accelerated pace (Figure 1, A and B) . His management was challenging. Dopamine agonists proved unsuccessful in suppressing GH hypersecretion; bromocriptine was initiated for the first 3 months but was later replaced with cabergoline (0.25-0.5 mg/wk) to control PRL levels. Long-acting somatostatin analog therapy induced a slight drop in GH but not in IGF-1 levels. Because the patient refused monthly injections (initially Sandostatin LAR and then Somatuline Autogel), after about 9 months, treatment was switched to continuous sc infusion of shortacting octreotide (5) at doses ranging from 120 -320 g/d. The combination of somatostatin analog and cabergoline was insufficient to normalize GH or IGF-1 levels. The addition of the GH receptor antagonist pegvisomant (30 -105 mg/wk) normalized IGF-1 and induced a plateau in his growth; the pituitary volume remained stable with this treatment combination ( Figure 1F ). Around the age of 7.5 years, the parents wished to reduce the dose of pegvisomant and short-acting octreotide therapy to allow controlled growth. They felt that he was destined to be a tall boy; thereafter his growth followed parallel to the 97th height percentile ( Figure 1A) , and his IGF-1 remained within the normal range.
Currently, at the age of 11 years, he remains well; his growth velocity is normal. He is on oral cabergoline 125 g thrice weekly, short-acting sc octreotide 222 g/24 h, and sc pegvisomant 20 mg twice weekly.
After the recent description of germline Xq26.3 microduplication in young children with acrogigantism (1), likely due to the duplicated GPR101 gene within this region, we tested the patient's leukocyte-, saliva-, and buccal cell-derived DNA using a comparative genomic hybridization array (BlueGnome CytoChip ISCA 8 ϫ 60k v2.0; Illumina) and copy number variation droplet digital PCR for GPR101 (Taqman assays Hs01818174_cn and Hs01730605_cn; Life Technologies) without evidence of Xq26.3 microduplications or GPR101 duplication, although his clinical phenotype was identical to the previously published patients. We therefore tested DNA isolated from the hyperplastic pituitary tissue and found duplicated dosage of GPR101 (Figure 2) . DNA extracted from a forearm skin biopsy also showed the microduplication, suggesting that he is mosaic for this mutation.
Ethics approval was granted from the Montreal Children's Hospital Research Ethics Board. Informed consent was obtained for all genetic analyses from the parents of this boy and for publication of this case report.
Discussion
XLAG often manifests in the first year of life and is more prevalent in girls. Unlike our case, all previously reported patients have had either sporadic or familial germline Xq26.3 microduplications allowing a definitive diagnosis on leukocyte-derived DNA. Because our case presented with a typical phenotype, we tested the pituitary tissue sample, and this showed GPR101 microduplication. One of the four different genomic DNA samples we tested from various tissues also showed GPR101 duplication, suggest- press.endocrine.org/journal/jceming that this patient has somatic mosaicism as a result of a postzygotic mutation. No cases of somatic mosaicism have been described previously in patients with XLAG syndrome. Treatment of XLAG is challenging. Previously described cases treated with surgery followed by medical treatment and/or radiotherapy have often developed hypopituitarism and central diabetes insipidus (1-3, 6) . Management of our patient with cabergoline, continuous sc infusion of short-acting somatostatin analog, and pegvisomant proved successful in controlling growth without hypopituitarism or other significant side effects.
Conclusion
This is the first report on a patient with documented somatic GPR101 duplication leading to XLAG. The case is instructive because it: 1) demonstrates that a negative genetic test for Xq26.3 microduplication or GPR101 duplication on peripheral blood DNA does not exclude the diagnosis of XLAG because it can result from a somatic mutation affecting the pituitary and possibly other tissues as a result of somatic mosaicism; and 2) proposes an effective combination and route of medical treatment for this condition that can be acceptable for young children.
